pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ELI LILLY CO · news · pharmadog
← back to ELI LILLY CO
News mentioning ELI LILLY CO
630
stories
16d
Verastem cancer drug shows early promise in small study
biopharma dive
16d
‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban
biospace
16d
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
biospace
16d
Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’
biospace
17d
Deep-pocketed Verdiva axes GLP-1 switching trial over ‘market evolution’
fiercebiotech
17d
Biomea posts phase 1 data to pitch oral GLP-1 to potential partners, but investors appear unconvinced
fiercebiotech
17d
Jazz CEO calls on industry to help rebuild momentum for leadership diversity
biospace
17d
Roche extends China deal streak with $1B pact for RNAi obesity drug
biopharma dive
17d
Pfizer pens $500M+ deal with Enodia to destroy disease-causing proteins
biospace
18d
Nurix drops one BTK degrader as momentum builds behind Roche-partnered option
fiercebiotech
18d
Pharma’s $500B patent problem will come in waves — not as a cliff
biopharma dive
18d
GSK pledges $800M to add biologics production capabilities in Pennsylvania
biospace
20d
The 2026 Biotech Graveyard
fiercebiotech
21d
FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts
biopharma dive
21d
TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms
biospace
21d
STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more
stat
22d
Chai Discovery signs GSK deal to make biologics with AI
endpoints
22d
TRex Bio prices $117M IPO to support immune drug work
biopharma dive
22d
GSK drinks in Chai Discovery’s AI models after wet-lab validation
fiercebiotech
22d
Pfizer pens $500M Enodia pact to join Lilly in emerging protein degrader field
fiercebiotech
22d
TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertension
endpoints
22d
Hengrui has become the go-to source of China biopharma innovation. What’s its secret?
fiercebiotech
22d
Lilly-backed TRex rakes in $117M IPO, while hypertension biotech Retension reveals $45M listing
fiercebiotech
22d
Eli Lilly and the LA Dodgers: A tale of 2 dynasties
biospace
22d
Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle
endpoints
22d
Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers
biospace
23d
AI biotech Iambic aims for $135M IPO to push cancer drugs through clinic
fiercebiotech
23d
Zealand, Roche’s ‘intriguing’ weight loss for amylin drug soured by blood sugar data
fiercebiotech
23d
Cerevance Parkinson’s drug shortens 'off time' in Ph. 3, paving path to FDA
biospace
23d
Biotech VC Forbion raises record $2.6B to support 30 ‘high-potential’ companies
biospace
← prev
page 3 of 21
next →
